Skip to main content

NCT00732875 - A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)

A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


Data Specification

Not Yet Available


Annotated CRF

Not Yet Available

Product Info

Generic Name
Infliximab
Product Name
REMICADE®
Therapeutic Area
Muscle, Bone, and Cartilage Diseases
Enrollment
92
Product Class
Antirheumatic agents - biologic response modifiers
Sponsor Protocol Number
P05645
Data Holder
Johnson & Johnson
Condition Studied
Arthritis, Rheumatoid

Supporting Documentation

Clinical Study Report
Protocol with Amendments
Study Phase 
3
Additional Information: 

Please note: Individual-participant level data are not available for this trial. However, the full Clinical Study Report can be provided.

APPROVED DATA REQUESTS ASSOCIATED WITH THIS TRIAL

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.